HomeREGULATORY
REGULATORY

CSIMC Recommends NHI Price Listing for 15 APIs/20 Products
(Sep.7.2011)

At a general meeting on September 7, the Central Social Insurance Medical Council (CSIMC; Chuikyo) recommended NHI price listing for 15 APIs (active pharmaceutical ingredients)/20 products, including AstraZeneca’s proton pump inhibitor (PPI) Nexium capsule 10 mg and 20 mg (esomeprazole magnesium) and Astellas Pharma’s treatment for overactive bladder Betanis Tablet 25 mg and 50 mg (mirabegron). The adrenal hormone preparation EpiPen Injection 0.15 mg and 0.3 mg (adrenaline) will be added to the NHI price list on September 22. Other products will be included in the NHI price list on September 12.
> Read full story

Commentary

As Adjuvant Development Race Heats Up, New Databases Could Turn Japan into Global Vaccine Powerhouse

Lexicon

Conditional, Time-Limited Approval:
条件・期限付き承認

The Column

Sales Experience for Marketers Deceasing in Japan’s Pharma Industry

Archives

Shionogi to Reorganize in April to Beat Biz Strategy Goals for FY2020(Feb.26)
MHLW OKs 60 New APIs in 2014, Doubling from Year Ago(Feb.26)
Avigan Shows Promise in Treatment of Ebola in Clinical Trial(Feb.26)
NanoCarrier Concludes Joint Research Agreement with Chugai to Develop Next-Generation Anticancer Drugs(Feb.26)
Eisai to File Halaven for Soft Tissue Sarcomas; PIII Study Results Show Significant Prolongation of OS(Feb.26)

Most Read

1.
Bristol-Myers F...
2.
Daiichi Sankyo ...
3.
Japan Generic S...
4.
Gilead’s Sofosb...
5.
MSD, Sanofi to ...

News Calendar